Sie sind bereits eingeloggt. Klicken Sie auf 2. tolino select Abo, um fortzufahren.
Bitte loggen Sie sich zunächst in Ihr Kundenkonto ein oder registrieren Sie sich bei bücher.de, um das eBook-Abo tolino select nutzen zu können.
In this book the authors review the field and explore the potential role of RNAi and other RNA technologies in cardiovascular medicine and research. They highlight the impressive recent progress but also the hurdles that still must be overcome before this promising technology is finally ready for translation and clinical use.
In this book the authors review the field and explore the potential role of RNAi and other RNA technologies in cardiovascular medicine and research. They highlight the impressive recent progress but also the hurdles that still must be overcome before this promising technology is finally ready for translation and clinical use.
MicroRNA.- An Overview of MicroRNA.- MicroRNAs and Their Potential.- miRNAs and Their Emerging Role in Cardiac Hypertrophy.- MicroRNAs and the Control of Heart Pathophysiology.- MicroRNA Systems Biology.- RNA Interference.- Targeting Viral Heart Disease by RNA Interference.- Design of siRNAs and shRNAs for RNA Interference: Possible Clinical Applications.- RNA Interference and MicroRNA Modulation for the Treatment of Cardiac Disorders.- Cardiac Delivery of Nucleic Acids by Transcriptional and Transductional Targeting of Adeno-Associated Viral Vectors.- Ribozymes.- Characterization of Hammerhead Ribozymes Potentially Suitable for the Treatment of Hyper-Proliferative Vascular Diseases.- Applications of Ribozymes and Pyrrole–Imidazole Polyamides for Cardiovascular and Renal Diseases.- Noncoding, Aptamer and Antisense RNAs.- Noncoding RNAs in Human Diseases.- Aptamers and siRNAs in Cardiovascular Disease.- Nucleic Acid Aptamers for Cardiovascular Therapeutics.- NF?B Decoy Oligodeoxynucleotide-Based Therapy in Cardiovascular Diseases.- Antisense Therapy for Restenosis Following Percutaneous Coronary Interventions.- Toxic RNA in Pathogenesis of Human Neuromuscular Disorders.
MicroRNA.- An Overview of MicroRNA.- MicroRNAs and Their Potential.- miRNAs and Their Emerging Role in Cardiac Hypertrophy.- MicroRNAs and the Control of Heart Pathophysiology.- MicroRNA Systems Biology.- RNA Interference.- Targeting Viral Heart Disease by RNA Interference.- Design of siRNAs and shRNAs for RNA Interference: Possible Clinical Applications.- RNA Interference and MicroRNA Modulation for the Treatment of Cardiac Disorders.- Cardiac Delivery of Nucleic Acids by Transcriptional and Transductional Targeting of Adeno-Associated Viral Vectors.- Ribozymes.- Characterization of Hammerhead Ribozymes Potentially Suitable for the Treatment of Hyper-Proliferative Vascular Diseases.- Applications of Ribozymes and Pyrrole-Imidazole Polyamides for Cardiovascular and Renal Diseases.- Noncoding, Aptamer and Antisense RNAs.- Noncoding RNAs in Human Diseases.- Aptamers and siRNAs in Cardiovascular Disease.- Nucleic Acid Aptamers for Cardiovascular Therapeutics.- NF?B Decoy Oligodeoxynucleotide-Based Therapy in Cardiovascular Diseases.- Antisense Therapy for Restenosis Following Percutaneous Coronary Interventions.- Toxic RNA in Pathogenesis of Human Neuromuscular Disorders.
MicroRNA.- An Overview of MicroRNA.- MicroRNAs and Their Potential.- miRNAs and Their Emerging Role in Cardiac Hypertrophy.- MicroRNAs and the Control of Heart Pathophysiology.- MicroRNA Systems Biology.- RNA Interference.- Targeting Viral Heart Disease by RNA Interference.- Design of siRNAs and shRNAs for RNA Interference: Possible Clinical Applications.- RNA Interference and MicroRNA Modulation for the Treatment of Cardiac Disorders.- Cardiac Delivery of Nucleic Acids by Transcriptional and Transductional Targeting of Adeno-Associated Viral Vectors.- Ribozymes.- Characterization of Hammerhead Ribozymes Potentially Suitable for the Treatment of Hyper-Proliferative Vascular Diseases.- Applications of Ribozymes and Pyrrole–Imidazole Polyamides for Cardiovascular and Renal Diseases.- Noncoding, Aptamer and Antisense RNAs.- Noncoding RNAs in Human Diseases.- Aptamers and siRNAs in Cardiovascular Disease.- Nucleic Acid Aptamers for Cardiovascular Therapeutics.- NF?B Decoy Oligodeoxynucleotide-Based Therapy in Cardiovascular Diseases.- Antisense Therapy for Restenosis Following Percutaneous Coronary Interventions.- Toxic RNA in Pathogenesis of Human Neuromuscular Disorders.
MicroRNA.- An Overview of MicroRNA.- MicroRNAs and Their Potential.- miRNAs and Their Emerging Role in Cardiac Hypertrophy.- MicroRNAs and the Control of Heart Pathophysiology.- MicroRNA Systems Biology.- RNA Interference.- Targeting Viral Heart Disease by RNA Interference.- Design of siRNAs and shRNAs for RNA Interference: Possible Clinical Applications.- RNA Interference and MicroRNA Modulation for the Treatment of Cardiac Disorders.- Cardiac Delivery of Nucleic Acids by Transcriptional and Transductional Targeting of Adeno-Associated Viral Vectors.- Ribozymes.- Characterization of Hammerhead Ribozymes Potentially Suitable for the Treatment of Hyper-Proliferative Vascular Diseases.- Applications of Ribozymes and Pyrrole-Imidazole Polyamides for Cardiovascular and Renal Diseases.- Noncoding, Aptamer and Antisense RNAs.- Noncoding RNAs in Human Diseases.- Aptamers and siRNAs in Cardiovascular Disease.- Nucleic Acid Aptamers for Cardiovascular Therapeutics.- NF?B Decoy Oligodeoxynucleotide-Based Therapy in Cardiovascular Diseases.- Antisense Therapy for Restenosis Following Percutaneous Coronary Interventions.- Toxic RNA in Pathogenesis of Human Neuromuscular Disorders.
Es gelten unsere Allgemeinen Geschäftsbedingungen: www.buecher.de/agb
Impressum
www.buecher.de ist ein Internetauftritt der buecher.de internetstores GmbH
Geschäftsführung: Monica Sawhney | Roland Kölbl | Günter Hilger
Sitz der Gesellschaft: Batheyer Straße 115 - 117, 58099 Hagen
Postanschrift: Bürgermeister-Wegele-Str. 12, 86167 Augsburg
Amtsgericht Hagen HRB 13257
Steuernummer: 321/5800/1497
